{
    "relation": [
        [
            "",
            "Simvastatin Plus Ezetimibe",
            "Placebo"
        ],
        [
            "Description",
            "A double-dummy method ensured that patients and study staff were unaware of the treatment allocation, with all patients taking 2 tablets during the first year (active simvastatin plus ezetimibe tablet with a placebo simvastatin tablet). After the first year, all patients took one tablet (active simvastatin 20mg plus ezetimibe 10mg tablet).",
            "A double-dummy method ensured that patients and study staff were unaware of the treatment allocation, with all patients taking 2 tablets (placebo simvastatin plus ezetimibe tablet with a placebo simvastatin tablet) during the first year. After the first year, all patients took one tablet (placebo simvastatin plus ezetimibe tablet)."
        ]
    ],
    "pageTitle": "Study of Heart and Renal Protection - Study Results - ClinicalTrials.gov",
    "title": "",
    "url": "https://clinicaltrials.gov/ct2/show/results/NCT00125593?sect=X0125&view=results",
    "hasHeader": true,
    "headerPosition": "MIXED",
    "tableType": "RELATION",
    "tableNum": 25,
    "s3Link": "common-crawl/crawl-data/CC-MAIN-2015-32/segments/1438042988718.8/warc/CC-MAIN-20150728002308-00256-ip-10-236-191-2.ec2.internal.warc.gz",
    "recordEndOffset": 864785359,
    "recordOffset": 864768330,
    "tableOrientation": "HORIZONTAL",
    "textBeforeTable": "Reporting Groups Run-in period between screening and randomization of ~ 6 weeks duration. 11792 patients screened and 9438 randomized to the initial 3 arms. Overall 9270 patients were randomly assigned to simvastatin plus ezetimibe (4650 patients, 4193 initially plus 457 after first year) versus placebo (4620 patients, 4191 initially plus 429 after first year). Significant events and approaches for the overall study following participant enrollment, but prior to group assignment Pre-Assignment Details SHARP was conducted in 380 centres in 18 countries: Austria, Australia, Canada, China, The Czech Republic, Denmark, Finland, France, Germany, Malaysia, The Netherlands, New Zealand, Norway, Poland, Sweden, Thailand, the United Kingdom and the United States of America. Recruitment occurred between 2003 and 2006. Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations Recruitment Details \u00a0 Hide Participant Flow \u00a0 Participant Flow Drug: Simvastatin 20 mg",
    "textAfterTable": "Participant Flow: \u00a0 Overall Study \u00a0 \u00a0 Simvastatin 20mg Plus Ezetimibe 10mg \u00a0 \u00a0 Placebo \u00a0 STARTED \u00a0 \u00a0 4650 \u00a0 \u00a0 4620 \u00a0 COMPLETED \u00a0 \u00a0 4549 \u00a0 \u00a0 4517 \u00a0 NOT COMPLETED \u00a0 \u00a0 101 \u00a0 \u00a0 103 \u00a0 \u00a0 Baseline Characteristics \u00a0 Hide Baseline Characteristics Population Description Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate. No text entered.",
    "hasKeyColumn": true,
    "keyColumnIndex": 0,
    "headerRowIndex": 0
}